Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Is there no place like home for an allogeneic stem cell transplant?

Bone Marrow Transplantation volume 55, pages 855–856 (2020)Cite this article

Subjects

“There is no place like home.” The Wonderful Wizard of Oz, by L. Frank Baum with Pictures by W.W. Denslow. Chicago: Geo. M. Hill Co. 1900. Retrieved January 16, 2020 from https://ia800609.us.archive.org/17/items/wond_wiz_oz/wonderfulwizardo00baumiala.

There is a health economic and patient outcome viewpoint in much of the developed world that complex medical treatment should, where possible be moved closer to home for as many patients as possible. In addition to this, moving treatment from the inpatient to the ambulatory setting has become an active area of clinical service improvement research with potential advantages to resource utilization and the patient experience. The paper by Gutiérrez-Garcia et al. [1] in this issue has shown that it is possible to instigate an “at-home” program for allogeneic haemopoietic stem cell transplantation (allo-HCT). Much of the world’s population is particularly underserved by access to allo-HCT [2] and any advances that would expand such availability would be of benefit to patients lacking other curative options. The Worldwide Network for Blood and Marrow Transplantation has been actively monitoring areas of need and helping to develop or expand programs in such areas with some success in the past decade [3].

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Gutiérrez-García G, Rovira M, Arab N, Gallego C, Sánchez J, Álvarez MÁ, et al. A reproducible and safe at-home allogeneic haematopoietic cell transplant program: first experience in central and Southern Europe. Bone Marrow Transplant.

  2. Niederwieser D, Baldomero H, Szer J, Gratwohl M, Aljurf M, Atsuta Y, et al. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transpl. 2016;51:778–85.

    Article  CAS  Google Scholar 

  3. Aljurf M, Weisdorf D, Hashmi S, Nassar A, Gluckman E, Mohty M, et al. Worldwide network for blood and marrow transplantation recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources, Part II: clinical, technical, and socioeconomic considerations. Biol Blood Marrow Transpl. 2019;25:2330–7.

    Article  Google Scholar 

  4. Von AhD, Spath M, Nielsen A, Fife B. The Caregiver’s role across the bone marrow transplantation trajectory. Cancer Nurs. 2016;39:E2–9.

    Google Scholar 

  5. Grimm PM, Zawacki KL, Mock V, Krumm S, Frink BB. Caregiver responses and needs. An ambulatory bone marrow transplant model. Cancer Pract. 2000;8:120–8.

    Article  CAS  Google Scholar 

  6. Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transpl. 2008;14:641–50.

    Article  CAS  Google Scholar 

  7. Martino M, Ciavarella S, De Summa S, Russo L, Meliambro N, Imbalzano L, et al. A comparative assessment of quality of life in patients with multiple myeloma undergoing autologous stem cell transplantation through an outpatient and inpatient model. Biol Blood Marrow Transpl. 2018;24:608–13.

    Article  Google Scholar 

  8. Dix SP, Geller RB. High-dose chemotherapy with autologous stem cell rescue in the outpatient setting. Oncology 2000;14:171–85.

    CAS  PubMed  Google Scholar 

  9. Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, et al. Outcomes of reduced-intensity conditioning allogeneic hematopoietic cell transplantation performed in the inpatient versus outpatient setting. Biol Blood Marrow Transpl. 2019;25:827–33.

    Article  Google Scholar 

  10. Rizzo JD, Vogelsang GB, Krumm S, Frink B, Mock V, Bass EB. Outpatient-based bone marrow transplantation for hematologic malignancies: cost saving or cost shifting? J Clin Oncol. 1999;17:2811–8.

    Article  CAS  Google Scholar 

  11. Hayes-Lattin B, Leis JF, Maziarz RT. Isolation in the allogeneic transplant environment: how protective is it? Bone Marrow Transpl. 2005;36:373–81.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Haematology, Peter MacCallum Cancer Centre, The Royal Melbourne Hospital, 305 Grattan, St Parkville, VIC, 3050, Australia

    Jeff Szer

Authors
  1. Jeff Szer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeff Szer.

Ethics declarations

Conflict of interest

The author declares that he has no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Szer, J. Is there no place like home for an allogeneic stem cell transplant?. Bone Marrow Transplant 55, 855–856 (2020). https://doi.org/10.1038/s41409-020-0828-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-020-0828-2

Search

Advanced search

Quick links